CytoDyn (CYDY) Non-Current Debt (2012 - 2023)

CytoDyn's (CYDY) quarterly Non-Current Debt came in at $714000.0 in Q2 2023, up 32.22% on a QoQ basis from $540000.0 in Q2 2014.

CytoDyn (CYDY) Non-Current Debt (2012 - 2023) Analysis & Trends

CytoDyn (CYDY) has 4 years of Non-Current Debt data on file, last reported at $714000.0 in Q2 2023.

Quarterly Non-Current Debt changed N/A year-over-year to $714000.0 in Q2 2023, while the trailing twelve-month figure through May 2023 was $714000.0 (changed N/A YoY) and the FY2023 annual result came in at $714000.0, changed N/A from the prior year.
Non-Current Debt rose to $714000.0 in Q2 2023, from $540000.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $714000.0 in Q2 2023 to a low of $714000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	CytoDyn	258.01 Mn	258.01 Mn	-	-

Download Data